Cannabis Science Negotiates a Total 360,000 Sq. Ft. Licensed Cannabinoid Grow and Formulation Processing in Nevada, Including Facilities for Educational and Medical Clinic and Laboratory for Drug Development Programs Targeting Multiple Critical Ailments
COLORADO SPRINGS, CO--(Marketwired - Mar 24, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced the Company has negotiated a major new drug development and facilities deal in the State of Nevada. The premises include an approximately 360,000 sq. ft. licensed cannabinoid grow and a separate formulation processing operation in Nevada. The transaction includes access to a separate educational and research facility for its drug development programs targeting critical ailment research initiatives.
All parties involved are motivated and excited to get this landmark deal underway. It gives the Company and its investor partners access to over 360,000 sq. ft. of fully-licensed land for cannabis grow operations and full access to an educational, laboratory, and medical clinic location for formulation processing and further critical ailment research.
"The goal is to bring our cannabinoid formulations across the country and internationally 'much faster' and more efficiently, and, in addition, to improve the Company's output capacity from a manufacturing standpoint. Sometimes opportunity just falls in your lap when you persevere in 'doing the right thing.' So now we move forward with this massive deal, which covers a large amount of land. We at Cannabis Science are so excited to see our widespread rollout strategy starting to come to fruition. This Nevada opportunity was a complete surprise as we were more focused on targeting California expansions; however, of course when new and fortuitous circumstances present themselves, you must be fluid, open and respond accordingly. This is what we did. The added capacity this development deal and others like it provides should allow us to rapidly move into a much larger development and production capacity, to continue the advancement of our drug development programs while we provide our important formulations to patients in need sooner and in greater geographic areas," stated Cannabis Science President & CEO, Co-Founder Raymond C. Dabney.
This added capacity will allow the Company to further its drug development programs more quickly. The Company has targeted current success with a few critical ailments including Cancer, PTSD, HIV/AIDS, Autism, and Neurological disorders, utilizing and monitoring different cannabinoid formulations and delivery modules. The Company will have a much wider base to work from by expanding into the State of Nevada, drawing another very large targeted medical consumer base.
"We have a few more landmark growth agreements underway, such as our California initiatives that are advancing nicely. The Company has more watershed operational changes to announce upon completion. We have a few more pleasant surprises to compound our growth and solidify our position in this outstanding cannabis-based pharmaceutical industry growth curve. We understand our position and we know what needs to get done. We are excited, we are motivated, and we are on the move, in the right direction. We look forward to keeping everyone up to date with all our progress. Again we wish to thank our shareholders for their continued support along this amazing path," concluded Mr. Dabney.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.